Moderna (NASDAQ:MRNA) projected 2025 sales at the upper end of its forecast as a smaller-than-expected decline in U.S. vaccination rates and aggressive cost-cutting help the biotech giant navigate the post-pandemic landscape.
KORU Medical Systems (NASDAQ:KRMD) reported preliminary 2025 revenue that exceeded the high end of its guidance on Monday, as the medical technology firm prepares to pivot from its core immunology business into the high-growth oncology market.
Cellares and Cabaletta Bio (NASDAQ:CABA) announced a landmark regulatory achievement Monday, with the FDA clearing an Investigational New Drug (IND) Amendment to manufacture the autoimmune-focused CAR T therapy, rese-cel, using Cellares’ fully automated platforms.
GeneDx Holdings Corp. (NASDAQ:WGS) issued a bullish outlook for 2026 on Monday, forecasting revenue to exceed the half-billion-dollar milestone as the company’s pivot to high-margin exome and genome sequencing gains unprecedented traction.
DexCom (NASDAQ:DXCM) projected its annual revenue will climb toward $5.25 billion in 2026, marking a pivotal year for the glucose-monitoring leader as it phases out older hardware in favor of its longest-lasting sensor technology to date.
AbbVie (NYSE:ABBV) secured exclusive global rights to a novel cancer-fighting antibody from RemeGen Co. on Monday, marking one of the year’s largest oncology licensing agreements as the pharmaceutical giant moves to integrate next-generation bispecifics with its expanding "ADC" platform.
SOPHiA GENETICS (NASDAQ:SOPH) reported a record-breaking performance for 2025, driven by a surge in demand for its AI-powered genomic analysis, as the company prepares for a major leadership transition and moves closer to profitability.
Viking Therapeutics (NASDAQ:VKTX) shares were in focus Monday after the company announced the peer-reviewed publication of its Phase 2 VENTURE study results, reinforcing the weight-loss potential of its lead candidate as it enters a pivotal year of Phase 3 testing.
OneSpaWorld Holdings Limited (NASDAQ:OSW) projected its annual revenue will surpass the $1 billion mark for the first time in 2026, as the company streamlines its global operations to capitalize on a record-breaking surge in cruise ship travel.
Zura Bio Limited 9NASDAQ:ZURA) announced it is expanding the patient population for its mid-stage trial of tibulizumab in hidradenitis suppurativa (HS), a move intended to bolster the study’s statistical power as the company prepares for a critical data readout later this year.
Summit Therapeutics (NASDAQ:SMMT) announced a clinical trial collaboration with GSK (NYSE:GSK) to evaluate the combination of ivonescimab, Summit’s novel investigational PD-1/VEGF bispecific antibody, with risvutatug rezetecan (GSK’227), GSK’s investigational B7-H3-targeting antibody-drug conjugate (ADC), in multiple solid tumor settings, including small cell lung cancer (SCLC).
West Pharmaceutical Services (NYSE:WST), a leading provider of injectable packaging and delivery systems, announced it has entered into a definitive agreement to sell all manufacturing and supply rights for its SmartDose 3.5mL On-Body Delivery System, along with associated facilities, to AbbVie (NYSE:ABBV) for $112.5 million in cash at closing, subject to customary working capital and other adjustments.
